Table. Demographic and Clinical Characteristics.
| MS (n = 550) | CIS (n = 49) | AQP4-positive NMOSD (n = 19) | Seronegative-NMOSD (n = 22) | MOGAD (n = 17) | Migraine (n = 96) | Inflammatory vasculopathies (n = 29) | Cerebrovascular disease (n = 63) | Fabry disease (n = 57) | Healthy control individuals (n = 149) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Male, No. (%) | 198 (36) | 15 (31) | 3 (16) | 3 (14) | 11 (65) | 20 (21) | 10 (34) | 29 (46) | 26 (46) | 48 (32) |
| Female, No. (%) | 352 (64) | 34 (69) | 16 (84) | 19 (86) | 6 (35) | 76 (79) | 19 (66) | 34 (54) | 31 (54) | 101 (68) |
| Age, mean (SD), y | 41.9 (12.5) | 37.2 (9.8) | 47.3 (14.1) | 47.3 (13.9) | 39.8 (11.7) | 42.3 (11.9) | 51.9 (15.7) | 63.2 (13.3) | 42.3 (12.5) | 51.4 (12.4) |
| Disease duration, median (IQR), y | 6.0 (1.5-13.5) | 0.4 (0.3-0.9) | 3.6 (1.9-5.0) | 7.0 (2.0-11.0) | 4.3 (0.6-7.8) | NA | NA | NA | NA | NA |
| EDSS score, median (IQR) | 2.0 (1.5-3.5) | 2.0 (1.0-2.5) | 3.25 (2.0-6.0) | 3.0 (2.0-5.0) | 1.5 (1.0-2.0) | NA | NA | NA | NA | NA |
| Disease subgroups, No. (%) | RRMS: 462 (84); SPMS: 62 (11); PPMS: 26 (5) | NA | NA | NA | NA | NA | Sjögren syndrome: 19 (66); SLE: 4 (14); Behçet disease: 3 (10); AAV: 2 (7); Susac syndrome: 1 (3) | CSVD: 53 (84); PFO: 10 (16) | NA | NA |
Abbreviations: AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; AQP4, aquaporin-4 antibody; CIS, clinically isolated syndrome; CSVD, cerebral small vessel disease; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease; MS, multiple sclerosis; NA, not applicable; NMOSD, neuromyelitis optica spectrum disorder; PFO, patent foramen ovale; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SLE, systemic lupus erythematosus; SPMS, secondary progressive multiple sclerosis.